Epstein–Barr Virus Driven Hodgkin’s Lymphoma after a Short Course of Daratumumab Treatment for Relapsed Multiple Myeloma
In this case, we describe the potential risk of developing an infectious complication leading to a secondary malignancy after a short course of immunotherapy. We report a patient who presented with Epstein–Barr virus (EBV) driven Hodgkin’s lymphoma after treatment with a short course of daratumumab...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2023/6669174 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559726659895296 |
|---|---|
| author | Moeen Mohammadi-Oroujeh Ansa Mehreen David L. Grinblatt |
| author_facet | Moeen Mohammadi-Oroujeh Ansa Mehreen David L. Grinblatt |
| author_sort | Moeen Mohammadi-Oroujeh |
| collection | DOAJ |
| description | In this case, we describe the potential risk of developing an infectious complication leading to a secondary malignancy after a short course of immunotherapy. We report a patient who presented with Epstein–Barr virus (EBV) driven Hodgkin’s lymphoma after treatment with a short course of daratumumab along with pomalidomide and dexamethasone for relapsed multiple myeloma. Although there have been limited documented cases of daratumumab treatment leading to EBV reactivation, in patients presenting with infectious symptoms or neutropenia on a daratumumab-based regimen, testing for EBV should not be overlooked. |
| format | Article |
| id | doaj-art-dde51a12d50a4430a52b4c45f31aa92b |
| institution | Kabale University |
| issn | 2090-6579 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-dde51a12d50a4430a52b4c45f31aa92b2025-02-03T01:29:30ZengWileyCase Reports in Hematology2090-65792023-01-01202310.1155/2023/6669174Epstein–Barr Virus Driven Hodgkin’s Lymphoma after a Short Course of Daratumumab Treatment for Relapsed Multiple MyelomaMoeen Mohammadi-Oroujeh0Ansa Mehreen1David L. Grinblatt2Department of Internal MedicineDepartment of PathologyDivision of HematologyIn this case, we describe the potential risk of developing an infectious complication leading to a secondary malignancy after a short course of immunotherapy. We report a patient who presented with Epstein–Barr virus (EBV) driven Hodgkin’s lymphoma after treatment with a short course of daratumumab along with pomalidomide and dexamethasone for relapsed multiple myeloma. Although there have been limited documented cases of daratumumab treatment leading to EBV reactivation, in patients presenting with infectious symptoms or neutropenia on a daratumumab-based regimen, testing for EBV should not be overlooked.http://dx.doi.org/10.1155/2023/6669174 |
| spellingShingle | Moeen Mohammadi-Oroujeh Ansa Mehreen David L. Grinblatt Epstein–Barr Virus Driven Hodgkin’s Lymphoma after a Short Course of Daratumumab Treatment for Relapsed Multiple Myeloma Case Reports in Hematology |
| title | Epstein–Barr Virus Driven Hodgkin’s Lymphoma after a Short Course of Daratumumab Treatment for Relapsed Multiple Myeloma |
| title_full | Epstein–Barr Virus Driven Hodgkin’s Lymphoma after a Short Course of Daratumumab Treatment for Relapsed Multiple Myeloma |
| title_fullStr | Epstein–Barr Virus Driven Hodgkin’s Lymphoma after a Short Course of Daratumumab Treatment for Relapsed Multiple Myeloma |
| title_full_unstemmed | Epstein–Barr Virus Driven Hodgkin’s Lymphoma after a Short Course of Daratumumab Treatment for Relapsed Multiple Myeloma |
| title_short | Epstein–Barr Virus Driven Hodgkin’s Lymphoma after a Short Course of Daratumumab Treatment for Relapsed Multiple Myeloma |
| title_sort | epstein barr virus driven hodgkin s lymphoma after a short course of daratumumab treatment for relapsed multiple myeloma |
| url | http://dx.doi.org/10.1155/2023/6669174 |
| work_keys_str_mv | AT moeenmohammadioroujeh epsteinbarrvirusdrivenhodgkinslymphomaafterashortcourseofdaratumumabtreatmentforrelapsedmultiplemyeloma AT ansamehreen epsteinbarrvirusdrivenhodgkinslymphomaafterashortcourseofdaratumumabtreatmentforrelapsedmultiplemyeloma AT davidlgrinblatt epsteinbarrvirusdrivenhodgkinslymphomaafterashortcourseofdaratumumabtreatmentforrelapsedmultiplemyeloma |